CONCISE REVIEW

The leading edge: Emerging neuroprotective and neuroregenerative cell-based therapies for spinal cord injury

Christopher S. Ahuja1,2,3 | Andrea Mothe3 | Mohamad Khazaei3 | Jetan H. Badhiwala1 | Emily A. Gilbert4 | Derek van der Kooy5 | Cindi M. Morshead2,4,6 | Charles Tator1,2,3 | Michael G. Fehlings1,2,3

1Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
2Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
3Department of Genetics and Development, Krembil Research Institute, UHN, Toronto, Ontario, Canada
4Division of Anatomy, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
5Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
6Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada

Correspondence
Michael G. Fehlings, PhD, MD, FRCSC, FACS, Toronto Western Hospital, 399 Bathurst Street, Suite 4W-449, Toronto, ON, Canada
Email: michael.fehlings@uhn.ca

Abstract
Spinal cord injuries (SCIs) are associated with tremendous physical, social, and financial costs for millions of individuals and families worldwide. Rapid delivery of specialized medical and surgical care has reduced mortality; however, long-term functional recovery remains limited. Cell-based therapies represent an exciting neuroprotective and neuroregenerative strategy for SCI. This article summarizes the most promising preclinical and clinical cell approaches to date including transplantation of mesenchymal stem cells, neural stem cells, oligodendrocyte progenitor cells, Schwann cells, and olfactory ensheathing cells, as well as strategies to activate endogenous multipotent cell pools. Throughout, we emphasize the fundamental biology of cell-based therapies, critical features in the pathophysiology of spinal cord injury, and the strengths and limitations of each approach. We also highlight salient completed and ongoing clinical trials worldwide and the bidirectional translation of their findings. We then provide an overview of key adjunct strategies such as trophic factor support to optimize graft survival and differentiation, engineered biomaterials to provide a support scaffold, electrical fields to stimulate migration, and novel approaches to degrade the glial scar. We also discuss important considerations when initiating a clinical trial for a cell therapy such as the logistics of clinical-grade cell line scale-up, cell storage and transportation, and the delivery of cells into humans. We conclude with an outlook on the future of cell-based treatments for SCI and opportunities for interdisciplinary collaboration in the field.

KEYWORDS
clinical trials, neuroprotection, neuroregeneration, spinal cord injury, stem cells

1 | INTRODUCTION

Spinal cord injuries (SCIs) have tremendous physical, social, and financial consequences for over 1 million North Americans and their
families. Direct lifetime costs of care range from $1.1 to $4.7 million per person not including lost wages and productivity. Rapid delivery of specialized medical and surgical care has significantly reduced mortality; however, long-term functional recovery remains limited. Cell-based therapies have emerged as an exciting strategy to neuroprotect and regenerate the injured cord through multiple mechanisms such as immunomodulation, paracrine signaling, extracellular matrix (ECM) modification, and lost cell replacement. Herein, we summarize the most promising preclinical and clinical cell therapies, adjunct strategies to enhance transplant success, as well as key translational considerations such as sex and age. Throughout, we emphasize the fundamental biology of stem cells, critical features in the pathophysiology of spinal cord injury and provide meaningful discussions on the strengths and limitations of each therapeutic approach.

1.1 Epidemiology

The epidemiology of SCI is an important consideration when designing clinical trials. Traumatic SCI is more common in males (79.8%) than females (20.2%). Most injuries are cervical (~60%) followed by thoracic (32%) and lumbosacral (9%). There is a bimodal age distribution with one peak occurring from 15 to 29 years of age and a second, smaller but growing peak, occurring after age 50. High-energy motor vehicle collisions (MVCs) and sports-related injuries disproportionately affect younger individuals. Low-energy trauma, such as falls, are more common in those over 60 years old where underlying degenerative spinal conditions, such as degenerative cervical myelopathy, are more prevalent. Interestingly, MVCs account for a declining majority (38%) of SCIs in North America, whereas falls are increasing and account for 31% of injuries followed by sports-related impacts at 10% to 17%.

2 PATHOPHYSIOLOGY

2.1 Acute injury and the postinjury milieu

The initial traumatic event causes permeabilization of cell membranes, ion and small molecule dysregulation, and ischemia due to damage to the sensitive microvascular supply. Together, these events initiate a secondary injury cascade which generates significant permanent damage (Figure 1A). Over several hours, progressive edema and hemorrhage cyclically add to the harsh postinjury milieu. The compromised blood-spinal cord barrier (BSCB) exposes the vulnerable cord to inflammatory cells, vasoactive peptides, and cytokines such as tumor necrosis factor and interleukin-1. Ongoing cell death releases DNA, ATP, and K+ into the microenvironment; microglia respond by secreting additional pro-inflammatory cytokines and promoting the infiltration of large numbers of macrophages, neutrophils, and nearby microglia. This activates astrocytes and endothelial cells which further secrete factors such as BMPs, TGF-β, and Notch activating ligand, Jagged. Activated phagocytes can clear myelin debris within the injury but also produce oxygen free radicals (eg, O2•−, peroxynitrite and hydrogen peroxide) and cytotoxic by-products which generate additional cell death through lipid peroxidation, protein oxidation, and DNA damage. Extracellular glutamate accumulates as neurons die and astrocytes’ reuptake capacity is lost. This leads to excitotoxic cell death of the remaining neurons through NMDA, kainate, and AMPA receptor overactivation combined with ATP-dependent ion pump dysfunction and subsequent sodium dysregulation.

At a systemic level, poor respiratory function can cause hypoxia whereas loss of sympathetic innervation to the vasculature can result in profound hypotension. Combined with the impaired autoregulatory capacity of the cord, this can contribute to ongoing ischemia for days to weeks postinjury. The multiple causes of acute and subacute cell death in this injury cascade represent important targets for cell-based neuroprotective approaches.

2.2 Barriers to recovery

In the intermediate-chronic phase, acute inflammation subsides and the cord undergoes alterations in ECM composition, attempts at remyelination, and remodeling of neural networks. Although this can result in limited recovery, multiple barriers to local circuit and long-tract regeneration persist. Neuroglial cell death and degeneration in the early phase disrupts the cord’s structural framework and leads to ex vacuo formation of microcystic cavitations containing extracellular fluid with thin bands of connective tissue. These cavities coalesce into larger collections which lack substrate for directed axonal regrowth and regenerative cell migration. Additionally, oligodendrocytes are susceptible to necrotic and apoptotic cell death. The denuded axons they leave behind cannot utilize rapid saltatory conduction and are particularly susceptible to nonfunctional electrogensis which further contributes to poor recovery.

Significance statement

Traumatic spinal cord injuries (SCIs) result in tremendous lifelong disability and financial burden for millions of patients and caregivers worldwide. Cell-based therapies have emerged as an exciting neuroprotective and neuroregenerative strategy for SCI. This review highlights key preclinical and clinical data in cell therapy with an emphasis on the pathobiology and mechanisms of recovery. Also discussed are adjunct treatments to maximize the efficacy of the grafts. Finally, important translational considerations such as clinical-grade scale-up and delivery techniques are discussed. The article succinctly provides readers with a working knowledge of SCI and cell therapies at the leading edge of research.
FIGURE 1 Pathophysiology of traumatic spinal cord injury. “(a) The initial mechanical trauma to the spinal cord initiates a secondary injury cascade that is characterized in the acute phase (that is, 0–48 hours after injury) by oedema, haemorrhage, ischaemia, inflammatory cell infiltration, the release of cytotoxic products and cell death. This secondary injury leads to necrosis and/or apoptosis of neurons and glial cells, such as oligodendrocytes, which can lead to demyelination and the loss of neural circuits. (b) In the subacute phase (2–4 days after injury), further ischaemia occurs owing to ongoing oedema, vessel thrombosis and vasospasm. Persistent inflammatory cell infiltration causes further cell death, and cystic microcavities form, as cells and the extracellular architecture of the cord are damaged. In addition, astrocytes proliferate and deposit extracellular matrix molecules into the perilesional area. (c) In the intermediate and chronic phases (2 weeks to 6 months), axons continue to degenerate and the astroglial scar matures to become a potent inhibitor of regeneration. Cystic cavities coalesce to further restrict axonal regrowth and cell migration.” Republished with permission from Ahuja et al.15
TABLE 1  Key preclinical studies of cell therapies for spinal cord injury

| Cell type | Species; source | SCI model; injury level; host; transplant interval; route of cell delivery; immunosuppression | Behavioral outcome | Histological outcome |
|-----------|----------------|----------------------------------------------------------------------------------|------------------|---------------------|
| BMSC      | Human BMSC<sup>51</sup> | T8 contusion (MASCIS Impactor; mild, moderate, severe); Sprague Dawley rats; subacute (7 days); epicenter injections in mild and severe injury, additional rostral and caudal injections in moderate injury group; cyclosporine immunosuppression (10 mg/kg/day s.c.) | Improvement in BBB score in mild SCI group at endpoint; in moderate SCI group BBB score higher at 1, 3, and 7 wk post-transplantation but not sustained; transient effect in severe SCI group; no improvement in grid walk and no difference in thermal sensitivity | In moderate SCI group more axons found within BMSC grafts relative to control; low graft survival in severe SCI group |
| BMSC      | Human BMSC<sup>52</sup> | T8-9 modified balloon compression; Wistar rats; subacute (7 days); intravenous injection; cyclosporine immunosuppression (10 mg/kg/day s.c.) | Improvement in BBB score at 21 and 28 days post-SCI | Transplanted BMSC detected in ventrolateral white matter and in segments rostral and caudal to injury epicenter |
| BMSC      | Adult rat BMSC<sup>53</sup> | T9 contusion (NYU impactor); Lewis rats; acute and subacute (7 days); epicenter and rostral and caudal injections; no immunosuppression | In acute groups, no difference between BMSC and control groups; in subacute groups, BMSC grafts improved BBB score | Better survival of grafts with subacute transplants; BMSC formed bundles bridging the epicenter of the injury |
| BMSC      | Adult rat BMSC<sup>54</sup> | T8-9 contusion (NYU impactor); Sprague Dawley rats; acute; epicenter injection; no immunosuppression | BMSC treated rats showed higher BBB with weight supported stepping | Less cavitation in BMSC group |
| BMSC      | Adult rat BMSC<sup>55</sup> | T8-9 contusion (NYU impactor; mild and severe SCI); Sprague Dawley rats; acute; intrathecal injection into fourth ventricle; FK506 immunosuppression | Improvement in BBB score for mild injury and at endpoint for severe SCI | Transplanted BMSC were found attached to spinal surface at initial time point and undetectable by 3 wk post-transplant; smaller lesion cavity in BMSC treated rats |
| BMSC      | Adult rat BMSC<sup>56</sup> | T8 contusion (OSU Impactor); Wistar rats; subacute (2 days); epicenter injection; group with additional injection at T11; no immunosuppression | No significant differences in BBB and subscore; more rats with BMSC grafts showed hindlimb astepping | Spared tissue area rostral and caudal to epicenter in BMSC transplanted groups; more axonal fibers at lesion site |
| BM-MNC    | Adult rat BM-MNC<sup>57</sup> | T8-9 balloon compression; Wistar rats; subacute (7 days); intravenous injection; Depo-Medrol immunosuppression (2 mg/rat/wk, i.m.) | Improvement in BBB score from 2 wk post-SCI | BMSC transplanted groups showed spared white matter rostral and caudal to epicenter, and some spared gray matter |
| Umbilical cord-derived MSC | Human umbilical cord-derived MSC<sup>58</sup> | T9 contusion (NYU); Sprague Dawley rats; subacute (7 days); intraspinal injection intraleosional | Improvement in BBB score from 2 wk after transplantation | Reduced cavity volume |
| Adipose-derived MSC | Human adipose-derived MSC<sup>59</sup> | T8-9 balloon compression; Sprague Dawley rats; acute; intraspinal injection rostral to lesion | Increased BBB score throughout time course | Tissue preservation, restricting inflammation, stimulation of axonal growth; laminin at lesion site associated with MSC grafts |
| NSPC and BMSC | Adult rat spinal cord derived NSPC alone or co-grafted with adult rat BMSC<sup>60</sup> | T8 clip compression; Sprague Dawley rats; subacute (9 days) transplants of NSPC, acute transplants of BMSC, alone or in combination; intraspinal rostral and caudal injections; cyclosporine immunosuppression (15 mg/kg/day s.c.) | Improved recovery on BBB and horizontal ladder with subacute NSPC transplants only | Grrafted NSPC ensheathed axons at injury site; increased sparing of long tracts |
| Cell type | Species; source | SCI model; injury level; host; transplant interval; route of cell delivery; immunosuppression | Behavioral outcome | Histological outcome |
|-----------|-----------------|---------------------------------------------------------------------------------|-------------------|---------------------|
| NSPC      | Adult rat spinal cord derived NSPC<sup>61</sup> | T8 clip compression; Sprague Dawley rats; acute, subacute (9 days) and chronic (6 wk); intraspinal rostral and caudal injections; cyclosporine immunosuppression (15 mg/kg/day s.c.) | Functional recovery only examined in acute transplant groups and no significant differences | NSPC transplants showed primarily glial differentiation; better graft survival with subacute transplants |
| NSPC      | Adult rat spinal cord derived NSPC and adult NSPC transduced to express neurogenin-2<sup>53</sup> | T8-9 contusion (weight drop); Sprague Dawley rats; subacute (7 days); intraspinal around the lesion site | Increased pain sensation with NSPC grafts but not with neurogenin-2 transduced NSPC which also showed improved BBB and grid walk scores | NSPC transplants primarily differentiated into astrocytes whereas neurogenin-2 transduced NSPC grafts showed neuronal phenotypes, enhanced myelination, white matter sparing, and axonal sprouting |
| NSPC      | Adult mouse SVZ derived NSPC<sup>53</sup> | T7 clip compression; Wistar rats; subacute (14 days) and chronic (56 days); intraspinal rostral and caudal injections; growth factors (EGF, bFGF, PDGF-AA) infused intrathecally at time of transplant for 1 wk; minocycline for 10 days (starting 3 days prior to transplantation); daily cyclosporine immunosuppression | Subacutely transplanted NSPC promoted recovery from 3 wk post-transplant on BBB; fewer footfalls on gridwalk; no improvement in chronic group | NSPC-derived oligodendrocytes produced MPB when transplanted subacutely; low survival in chronic transplants |
| NSPC      | Adult mouse SVZ derived NSPC<sup>53</sup> | T7 clip compression; Wistar rats; chronic (7 wk); intraspinal rostral and caudal injections; ChABC infused intrathecally 1 wk prior to transplant; growth factors (EGF, bFGF, PDGF-AA) infused intrathecally at time of transplant for 1 wk; minocycline for 10 days; daily cyclosporine immunosuppression | Improved BBB score and fewer footfall errors on grid walk with combination treatment; grafts did not cause allodynia | ChABC infusion reduced CSPG and improved NSPC graft survival; NSPC primarily differentiated into oligodendrocytes; combination enhanced axonal plasticity |
| NSPC      | Human fetal NSPC (hCNS-SC)<sup>54</sup> | T9 contusion (Infinite Horizon); NOD-SCID mice; subacute (9 days) | Improvement in BBB and horizontal ladder beam task in NSPC group; effects lost when diphtheria toxin was used to kill the grafted cells | Neuronal differentiation of grafted cells; wrapping of spared axons |
| NSPC      | Human fetal NSPC<sup>65</sup> | C5 contusion (modified NYU impactor); common marmosets; subacute (9 days); epicenter injection; cyclosporine (10 mg/kg/day) | NSPC transplants improved bar grip power and spontaneous motor activity | Axonal bundles in NSPC grafts filling lesion; MRI shows smaller lesions in NSPC transplanted group |
| iPSC-derived NSPC | Human iPSC-derived NSPC<sup>66</sup> | T10 contusion (Infinite Horizon); NOD-SCID mice; subacute (9 days); epicenter injections | Improvement in BMS score and rotarod test | Grafted cells expressed neurotrophic factors; stimulation of angiogenesis and axonal growth; increased myelination; synapse formation between graft-derived neurons and host neurons |

(Continues)
| Cell type | Species; source | SCI model; injury level; host; transplant interval; route of cell delivery; immunosuppression | Behavioral outcome | Histological outcome |
|-----------|----------------|-------------------------------------------------------------------------------------------------|-------------------|---------------------|
| iPSC-derived NSPC | Human iPSC-derived NSPC | T9-10 contusion (Infinite Horizon); NOD-SCID mice; subacute (7 days); epicenter injections | Improvement in BMS at 2 wk post-transplantation and motor-evoked potentials | Sparing of endogenous neurons; synapse formation between graft-derived neurons and host neurons |
| ESC-derived OPC Mouse ESC-derived NSPCs | Human ESC-derived OPC | T9-10 contusion (NYU); Long Evans rats; subacute (9 days); intraspinal into lesion site; cyclosporine (10 mg/kg/day s.c.) | Improvement in BBB at 5 wk post-transplantation | Grafted cells differentiated into neuronal and glial phenotypes |
| ESC-derived OPC Human ESC-derived OPC | T8-11 contusion (Infinite Horizon); Sprague Dawley rats; subacute (10 mo); intraspinal rostral and caudal injections; cyclosporine (10 mg/kg/day s.c.) | Subacutely transplanted hESC-derived OPC promoted recovery from 3 wk post-SCI on BBB and certain gait parameters; no improvement in chronic groups | Subacute transplants increased oligodendrocyte remyelination and decreased the density of demyelinated axons; no change in chronic groups |
| ESC-derived OPC Human ESC-derived OPC | C5 contusion (Infinite Horizon); Sprague Dawley rats; subacute (7 days); intraspinal rostral and caudal injections; cyclosporine (20 mg/kg/day s.c.) | Improved specific gait parameters of forelimb motor function | Tissue sparing; preservation of motor neurons |
| Schwann Cells Adult human Schwann cells; peripheral nerve | 4-5 mm segment of cord removed at T8; athymic nude rats; Schwann cells implanted acutely in PAN/PVC channels; in combination with methylprednisolone (30 mg/kg, i.v to all animals at 5 min, 2 and 4 hours) | Rats implanted with bridging Schwann cell grafts in PAN/PVC channels showed higher scores on BBB and inclined plane at 6 wk post-SCI | Schwann cell grafts without channels showed more myelinated fibers than grafts in channel; 5-HT+, CGRP+ axons were present within the grafts but did not exit grafts |
| Schwann Cells and OEC Adult rat Schwann cells and OEC from nerve fiber layer | T9 contusion (NYU impactor); Fischer rats; subacute (7 days); intraspinal injection into lesion of Schwann cells, OEC, or Schwann cell + OEC grafts | Improved BBB score in Schwann cell group only | More myelinated axons in Schwann cell grafts compared to OEC or OEC + Schwann cell; less cavitation and more sparing in all grafted groups |
| Schwann Cells and OEC Adult rat Schwann cells and OEC from olfactory bulb | T9 contusion (NYU/MASCIS); Fischer rats; chronic (8 wk); intraspinal injections of Schwann cell or OEC grafts | Schwann cell but not OEC grafts improved BBB score and base of support and hindpaw rotation in footprint analysis | Schwann cells survived better than OEC and Schwann cell grafts contained more sensory axons but not CST ingrowth |
| Schwann Cells and OEC Adult rat Schwann cells and OEC from olfactory bulb | T9 contusion (NYU/MASCIS); Fischer rats; subacute (7 days); intraspinal injections of Schwann cells, OEC, or Schwann cell + OEC grafts | Improved BBB score only with Schwann cell + OEC grafts but no improvement in gait parameters | More myelinated axons found within regions of grafted Schwann cells but not OEC; both grafts increased host Schwann cell infiltration but no sensory or supraspinal axon ingrowth; OEC grafts survived poorly |
| OEC Adult rat OEC from olfactory bulb | Cervical CST hemisection; acute; intraspinal transplant into lesion site | Rats in which OEC grafts formed continuous bridge across lesion were able to use affected forepaw for directed reaching | OEC grafts promoted growth of lesioned axons |
| OEC Adult rat OEC | T8/T9 complete transection; acute; intraspinal transplants into cord stumps | Improved locomotor function and sensorimotor reflexes in climbing test | Regeneration of motor axons caudally in OEC grafts |
Early after injury, astrocytes also proliferate within the perilesional zone and tightly interweave an irregular mesh of processes to sequester the injured region (Figure 1C). Resident neural stem and progenitor cells surrounding the central canal can also differentiate to astrocytes and contribute to this astrogliosis. The astrocytes, pericytes, and ependymal cells in the region generate dense deposits of chondroitin sulfate proteoglycans (CSPGs), NG2, and tenasin which form the fibrous component of the glial scar.29-32 Although literature exists supporting the beneficial aspects of scar, the balance of evidence suggests that chronic scarring potently inhibits axonal regeneration and neurite outgrowth by acting as a physical barrier and tightly binding transmembrane protein tyrosine phosphatase receptors.33-35

Furthermore, CNS myelin- and neuron-associated ligands, such as myelin associated glycoprotein (MAG), oligodendrocyte myelin glycoprotein (OMgp), neurite outgrowth inhibitor (NOGO), and semaphorin 3A/4D, bind NOGO receptor-p75 complexes (NgR) and plexins to activate Rho GTPase and its downstream effector, Rho-associated protein kinase (ROCK).36-39 This results in a change in actomyosin contractility and collapse of the axonal growth cone and further inhibition of regeneration. There are other potent inhibitors of axonal regeneration such as Repulsive Guidance Molecule A which are upregulated in the injured cord.40-42

Multiple cell strategies discussed below aim to preserve and/or regenerate functional, myelinated neural circuits to enhance functional recovery.

3  |  CELL-BASED THERAPIES

Cell-based therapies include cell transplantation and harnessing the potential of endogenous neural precursor cells. Cell treatments can immunomodulate, alter the microenvironment, and replace lost cells depending on the cell type, cell state, delivery route (eg, systemic vs local), and timing of administration.43-46 The most commonly studied and promising cell types include mesenchymal stem cells (MSCs), neural stem cells (NSCs), oligodendrocyte progenitor cells (OPCs), Schwann cells (SCs), and olfactory ensheathing cells (OECs).47-50 This section outlines the mechanisms of action for each and summarizes progress along the translational research spectrum. Key preclinical studies are highlighted in Table 1, and completed and ongoing clinical trials are summarized in Tables 2 and 3, respectively.

3.1  |  Cell source

MSCs, SCs, and OECs can all be harvested from an adult allogeneic source to generate standardized stocks depending on the success of proliferation. MSCs, SCs, and OECs can also be derived directly from the patient to avoid post-transplant immunosuppression.54 However, autologous primary cells are typically more costly requiring harvest surgery, in vitro expansion and extensive characterization prior to transplant.

CNS cells, such as NSCs, OPCs, astrocytes and microglia, are more challenging to isolate from adult allogeneic donors, and the performance of a line is influenced by donor age, genetics, and harvest conditions.85-87 Furthermore, autologous CNS tissue is inaccessible. As a result, these cells are often derived from embryonic stem cell (ESC) sources.88,89 ESCs can be propagated indefinitely and can generate cells of any germ layer. However, ESC-derived grafts have ethical issues surrounding their use and may show karyotypic instability or hold the potential for tumorigenesis due to incomplete or aberrant differentiation. More recently, induced pluripotent stem cells (iPSCs) have allowed derivation of NSCs and OPCs from autologous, accessible cells such as bone marrow and skin fibroblasts. This has been further adapted to allow direct reprogramming of adult somatic cells to multipotent neuronal cells while bypassing the pluripotent state.7 In more recent protocols, it has also become possible to convert easily accessible somatic cells directly into neurons,90,91 neuronal subtypes,92,93 and oligodendrocytes progenitors.94 Some limitations associated with these approaches such as reprogramming efficiency, line variability, lineage-specific differentiation, and retention of epigenetic memory are being investigated.

3.2  |  Neural stem cells

NSCs are tripotent, self-renewing cells which have attracted great interest as they can potentially replace the neurons, oligodendrocytes, and astrocytes lost after injury.88,95-97 During embryological development, NSCs are found throughout the neural tube where they acquire unique identities based on their position and temporal exposure to patterning morphogens.98-101 In adults, they are found in a more limited number of regions such as the subventricular zone in the brain,95-97 and around the central canal in the spinal cord.102-105 There are two distinct NSC populations that can be isolated from the adult spinal cord: (a) primitive NSCs (pNSCs) and (b) the definitive NSCs (dNSCs) they give rise to (Figure 2).106,107 pNSCs are rare cells expressing pluripotency marker, Oct4, and are responsive to leukemia inhibitory factor in vitro.108-110 dNSCs are more abundant in adults, express astrocyte marker, GFAP, and respond to epidermal and fibroblast growth factors (EGF and FGF) in vitro. Both populations can proliferate and generate neurons, astrocytes and oligodendrocytes.

Numerous small and large animal preclinical studies have provided evidence supporting the therapeutic efficacy of transplanting NSCs derived from ESCs or allogeneic adult sources.60,62,84 More recently, autologous iPSC-derived and directly reprogrammed NSCs have emerged as translationally relevant options which mitigate immunorejection concerns and generate highly pure populations of cells over several weeks. A 2016 meta-analysis (N = 74 studies) found all sources of NSCs to provide significant motor recovery in models of SCI (pooled SMD = 1.45; 95% confidence interval [CI]: 1.23-1.67; P < .001).111 Although the mechanisms underlying recovery continue to be investigated in preclinical studies, it is likely that trophic signaling (eg, BDNF, GDNF, IGF-1, etc.), remyelination of denuded axons,
### TABLE 2  Key completed clinical trials of cell therapies for spinal cord injury

| Cell type | Sponsor, country | Phase; Clinicaltrials.gov identifier | # Participants; age | Injury level; severity; transplant interval after SCI | Route of cell delivery | Completion date |
|-----------|------------------|--------------------------------------|--------------------|-----------------------------------------------------|------------------------|-----------------|
| **Autologous BMSC** | Puerta de Hierro University Hospital, Spain | Phase II; NCT02570932 | 10; 18-70 yr | ASIA A-D; more than 6 mo | Intrathecal; 3 injections 3 mo apart | Dec 2017 |
| **Autologous BMSC** | Indian Spinal Injuries Centre, India | Phase I/II; NCT02260713 | 21; 18-50 yr | T1-T12; ASIA A; 10-14 days | Intrathecal (single injection) or intraspinal | Nov 2017 |
| **Autologous BMSC** | Hospital Sao Rafael, Brazil | Phase I; NCT01325103 | 14; 18-50 yr | Thoracic and lumbar; ASIA A; more than 6 mo | Intraspinal | Dec 2012 |
| **Autologous BMSC** | International Stemcell Services Limited, India | Phase I; NCT01186679 | 12; 20-55 yr | C4-T12; ASIA A-C; acute within 2 wk, subacute 2-8 wk, chronic more than 6 mo | Intrathecal for acute and subacute; intraspinal for chronic | Aug 2010 |
| **Autologous BMSC** | Cairo University, Egypt | Phase I/II; NCT00816803 | 80; 10-36 yr | C3-T12; ASIA A-B; 10 mo to 3 yr | Intrathecal | Dec 2008 |
| **Autologous MSC** | Hospital Sao Rafael, Brazil | Phase I; NCT02152657 | 5; 18-65 yr | T8 and below; ASIA A; more than 6 mo | Percutaneous injection | Dec 2016 |
| **Autologous Adipose-derived MSC** | Biostar, Korea University Anam Hospital, Korea | Phase I/II; NCT01769872 | 15; 19-70 yr | ASIA A-C; more than 3 mo | Intravenous, intrathecal, and intraspinal; each single injections | Jan 2016 |
| **Autologous Adipose-derived MSC** | Biostar, Anyang Sam Hospital, Korea | Phase I; NCT01274975 | 8; 19-60 yr | ASIA A-C; more than 2 mo | Intravenous, single injection | Feb 2010 |
| **Autologous BMSC vs Adipose-derived MSC** | University of Jordan, Jordan | Phase I/II; NCT02981576 | 14; 18-70 yr | ASIA A-C; more than 2 wk | Intrathecal; total of three injections | Jan 2019 |
| **Autologous BM-MNC** | Armed Forces Bone Marrow Transplant Center, Pakistan | Phase I; NCT02482194 | 9; 18-50 yr | Thoracic; ASIA A; more than 2 wk | Intrathecal | Mar 2016 |
| **Autologous BM-MNC** | Neurogen Brain and Spine Institute, India | Phase I; NCT02027246 | 166; 8 mo to 63 yr | Any SCI | Intrathecal | Feb 2013 |
| **Autologous BM-MNC** | China Spinal Cord Injury Network, China | Phase I/II; NCT01354483 | 20; 18-60 yr | C5-T11; ASIA A; more than 1 yr | Intraspinal; dose escalation | Dec 2013 |
| **Human Central Nervous System Stem Cells (HuCNS-SC)** | StemCells, Inc, Canada and Switzerland | Phase I/II; NCT01321333 | 12; 18-60 yr | T2-T11; ASIA A-C; 3-12 mo | Intraspinal | Apr 2015 |
| **Human Central Nervous System Stem Cells (HuCNS-SC)** | StemCells, Inc, Canada and United States | Phase II; NCT02163876; terminated (based on a business decision unrelated to any safety concerns) | 31; 18-60 yr | C5-C7; ASIA B-C; more than 12 wk | Intraspinal | May 2016 |
| **ESC-derived OPC (GRNOPC1)** | Asterias Biotherapeutics, Inc, United States | Phase 1; NCT01217008 | 5; 18-65 yr | T3-T11; ASIA A; 1-2 wk | Intraspinal | July 2013 |
| **ESC-derived OPC (AST-OPC1)** | Asterias Biotherapeutics, Inc, United States | Phase I/IIa; NCT02302157; | 25; 18-69 yr | C4-7; ASIA A-B; 21-42 days | Intraspinal; dose escalation study | Dec 2018 |
TABLE 2 (Continued)

| Cell type                  | Sponsor, country                  | Phase; Clinicaltrials.gov identifier | # Participants; age | Injury level; severity; transplant interval after SCI | Route of cell delivery | Completion date |
|----------------------------|-----------------------------------|-------------------------------------|--------------------|------------------------------------------------------|------------------------|-----------------|
| Autologous Human Schwann Cells (ahSC) | The Miami Project to Cure Paralysis, University of Miami, United States | Phase I; NCT01739023              | 9; 18-60 yr        | T3-T11; ISNCSCI grade A; 30-72 days                   | Intraspinol             | Aug 2016^50     |
| Autologous Human Schwann Cells (ahSC) | The Miami Project to Cure Paralysis, University of Miami, United States | Phase I; NCT02354625; recruiting | 8; 18-65 yr        | C5-T12; ASIA A-C; more than 12 mo                   | Intraspinol             | Aug 2019        |

Note: Clinical trials that are completed are identified with the NCT number listed on www.ClinicalTrials.gov. Published results of clinical trials, if available, are referenced.

Abbreviations: BM-MNC, bone marrow-derived mononuclear cells; BMSC, bone marrow-derived mesenchymal stem cells; ESC, embryonic stem cell; ISNCSCI, International Standards for Neurological Classification of Spinal Cord Injury; MSC, mesenchymal stem cells; NSPC, neural stem/progenitor cells; OPC, oligodendrocyte precursor cells.

partial regenration and remodeling of neural circuitry, and ECM deposition play a role.7^8,112 Recent work demonstrating the self-assembly of grafted spinal cord NSCs into organotypic, dorsal horn-like domains highlights their plasticity and the potential for further optimization as a therapy.113

Currently, a phase I/II study in China (N = 30; NCT02688049) is comparing 1 x 10^5 MSCs vs NSCs supported by a linearly ordered collagen biomaterial, NeuroRegen scaffold, in individuals with chronic AIS Grade A C5-T12 injuries. The study is expected to conclude in 2020 and report on AIS grade, somatosensory evoked potentials, motor evoked potentials, Functional Independence Measure, and MRI assessments. Neuralstem is also conducting a trial (N = 8; NCT01772810) of NSI-566, human fetal spinal cord NSCs, delivered through six intraspinal injections into patients with 1 to 2 year old thoracic injuries. In 2016, a pair of phase II trials led by Stem Cells Inc were terminated prior to completion. The studies were assessing the effects of human CNS stem cell transplants for thoracic (NCT01321333) and cervical (NCT02153876) SCI.114 A recently published report on the studies found that escalating doses up to 4.0 x 10^6 were well tolerated with no significant increase in serious adverse events related to the cells or free-hand manual injection technique.83 Based on emerging preclinical data, it is likely that further modifying the cells in vitro and/or altering the local environment will be necessary to enhance functional recovery.

3.3 Oligodendrocyte progenitor cells

OPCs are tripotent cells which predominantly differentiate into oligodendrocytes to remyelinate axons. They are suited for regeneration in SCI as they respond rapidly to injuries, can self-renew, and address an important component of the injury pathophysiology. Animal studies have shown that transplanted OPCs can promote white matter preservation, increase the number of surviving endogenous oligodendrocytes, and reduce cavity volume, resulting in enhanced motor recovery. The underlying mechanism may be a combination of remyelination, local immunomodulation, trophic factor secretion, and provision of a physical scaffold to support growing axons.69,70,115,116 The cells also possess a favorable secretome,117 consisting of growth factors, neurotrophins, chemokines and cytokines, and can form glutamatergic synapses with neurons, an area of ongoing discovery.118 It remains unclear whether improved outcomes are due to these factors or direct remyelination of denuded axons, and to what extent remyelination can itself enhance function after injury.119,120

A large clinical trial by Geron Inc assessing human ESC-derived OPCs was discontinued for financial reasons. Renewed funding allowed Asterias Biotherapeutics Inc to extend the trial of these cells, termed AST-OPC1, in a phase I/IIa open-label dose-escalation study (N = 25; NCT02302157). 2 x 10^6, 1 x 10^7, or 2 x 10^7 cells were transplanted 21 to 42 days after SCI patients with AIS grade A or B injuries at C4 to C7. The study completed in 2019 and BioTime, which later changed its name to Lineage Cell Therapeutics, acquired the company. Key findings were no increase in significant adverse events and evidence of regeneration on MRI at 12 months. Ninety-five percent of patients improved by at least 1 AIS grade and 32% of patients improved by at least 2 AIS grades by 12 months after receiving the 1 x 10^7 and 2 x 10^7 doses.114 Longer term follow-up is continuing and the company plans to further optimize the cell manufacturing process.121

3.4 Olfactory ensheathing cells

OECs are specialized glial cells that encircle olfactory neurons and clear bacteria and debris at the CNS-nasal mucosa transition.122-125 They also secrete neurotrophic factors126 and maintain a favorable environment for neuronal function. When the olfactory nerve or epithelium is damaged, OECs support the growth of olfactory epithelium-derived neurons into the olfactory bulb. They differ from typical glia but share a number of morphological and molecular markers with astrocytes and SCs. After transplantation, OECs form a cellular substrate through which injured axons can regenerate across a spinal cord.

```
OECs can be harvested from the nasal mucosa or directly from the olfactory bulb and transplanted into the cord parenchyma as a bridging, nonrelay approach. OECs have also been shown to enhance neurite outgrowth, promote remyelination, neuroprotect, provide guidance cues, and locally immunomodulate. Several clinical trials have transplanted OECs for subacute and chronic SCI. Early work confirmed the safety of a purified population of OECs; however, subsequent studies using mucosal tissue reported conflicting results. To clarify the discrepancy, a meta-analysis of key clinical trials (pooled N = 1193) was conducted which found no statistically significant increase in serious adverse events; however, efficacy has not been definitively established due to technical and methodological concerns with existing studies. Recently, a small phase I trial (N = 6) of autologous mucosal OECs and olfactory fibroblasts demonstrated sensorimotor improvements after transplant into

### TABLE 3 Key ongoing clinical trials of cell therapies for spinal cord injury

| Cell type                  | Sponsor, country                  | Phase; Clinicaltrials.gov identifier; study status | Estimated enrollment; age | Injury level; severity; transplant interval after SCI | Route of cell delivery | Estimated completion date |
|----------------------------|-----------------------------------|---------------------------------------------------|---------------------------|-------------------------------------------------------|------------------------|---------------------------|
| Autologous MSC             | Hospital Sao Rafael, Brazil       | Phase I; NCT02574572; recruiting                  | 10; 18-65 yr             | C5-C7; ASIA A; more than 12 mo                        | Intraspinal            | Jun 2020                  |
| Autologous MSC             | Hospital Sao Rafael, Brazil       | Phase II; NCT02574585; not recruiting             | 40; 18-65 yr             | T1-L2; ASIA A; more than 12 mo                        | Percutaneous; 2 injections 3 mo apart | Jan 2022                  |
| Autologous MSC             | Pharmicell Co., Ltd., Seoul, Korea| Phase II/III; NCT01676441; active, not recruiting | 32; 16-65 yr             | Cervical; ASIA B; more than 12 mo                     | Intraspinal and intrathecal | Dec 2020                  |
| Autologous Adipose-derived MSC | Allan Dietz, Mayo Clinic, United States | Phase I; NCT03308565; recruiting                  | 10; 18 yr and older      | ASIA A-B; 2 wk to 1 yr                               | Intraspinal; single injection | Nov 2023                  |
| Autologous BM-MNC          | Da Nang Hospital, Vietnam         | Phase II/II; NCT02922817; recruiting              | 30; 20-60 yr             | ASIA A-B; 3 wk to 12 mo                              | Intraspinal            | Jun 2019^1               |
| Allogeneic UC-derived MSC  | The Third Affiliated Hospital, Sun Yat-Sen University, Guangdong, China | Phase I/II; NCT03505034; recruiting                | 43; 18-65 yr             | ASIA A-D; more than 12 mo                            | Intrathecal            | Dec 2021                  |
| Allogeneic UC-derived MSC  | Limin Rong, Third Affiliated Hospital, Sun Yat-Sen University, Guangdong, China | Phase I/II; NCT02481440; recruiting                | 44; 18-65 yr             | ASIA A-D; more than 2 wk                             | Intrathecal; monthly injections for 4 mo | Dec 2018^2               |
| Allogeneic UC-derived MSC  | The Third Affiliated Hospital, Sun Yat-Sen University, Guangdong, China | Phase I/II; NCT03521323; recruiting                | 92; 18-65 yr             | ASIA A-D; 2-12 mo                                    | Intrathecal; monthly injections for 4 mo | Dec 2022                  |
| Allogeneic UC-derived MSC  | The Third Affiliated Hospital, Sun Yat-Sen University, Guangdong, China | Phase I/II; NCT03521336; recruiting                | 130; 18-65 yr            | ASIA A-D; subacute (2 wk to 2 mo), early chronic (2-12 mo), chronic (more than 12 mo) | Intrathecal; monthly injections for 4 mo | Dec 2022                  |
| Allogeneic WJ-derived MSC  | Banc de Sang i Teixits, Barcelona, Spain | Phase I/II; NCT03003364; active, not recruiting   | 10; 18-65 yr             | T2-T11; ASIA A; 1-5 yr                               | Intrathecal            | Apr 2020                  |
| Human Spinal Cord-derived NSC | Neuralstem Inc, United States | Phase I; NCT01772810; recruiting                 | 8; 18-65 yr              | T2-T12 or C5-C7; ASIA A; 1-2 yr                      | Intraspinal            | Dec 2022                  |
| Autologous OEC             | Wroclaw Medical University, Poland | Phase I; NCT01231893; unknown status             | 10; 16-65 yr             | C5-L5; ASIA A; Interval N/A                           | Intraspinal            | N/A^3                     |

Note: Clinical trials currently recruiting or ongoing are identified with the NCT number listed on www.ClinicalTrials.gov. Abbreviations: BM-MNC, bone marrow-derived mononuclear cells; BMSC, bone marrow-derived mesenchymal stem cells; ESC, embryonic stem cell; MSC, mesenchymal stem cells; NSPC, neural stem/progenitor cells; OEC, olfactory ensheathing cells; OPC, oligodendrocyte precursor cells; UC-derived MSC, umbilical cord-derived mesenchymal stem cells; WJ-derived MSC, Wharton’s jelly-derived mesenchymal stem cells.

^1 Status unknown or not updated on clinicaltrials.gov.

The transection lesion site. OECs can be harvested from the nasal mucosa or directly from the olfactory bulb and transplanted into the cord parenchyma as a bridging, nonrelay approach. OECs have also been shown to enhance neurite outgrowth, promote remyelination, neuroprotect, provide guidance cues, and locally immunomodulate. Several clinical trials have transplanted OECs for subacute and chronic SCI. Early work confirmed the safety of a purified population of OECs; however, subsequent studies using mucosal tissue reported conflicting results. To clarify the discrepancy, a meta-analysis of key clinical trials (pooled N = 1193) was conducted which found no statistically significant increase in serious adverse events; however, efficacy has not been definitively established due to technical and methodological concerns with existing studies. Recently, a small phase I trial (N = 6) of autologous mucosal OECs and olfactory fibroblasts demonstrated sensorimotor improvements after transplant into...
patients with AIS grade A injuries; however, a larger sample size and extended follow-up will be required to confirm safety and efficacy.\textsuperscript{45,129,131}

3.5 | Schwann cells

SCs are myelinating cells in the peripheral nervous system (PNS) and are an important component of the robust, spontaneous regeneration observed in the PNS. They provide a structural scaffold acting as a conduit to guide growing axons. They also produce a favorable environment by expressing growth factors and extracellular proteins. In animal models of SCI, they have been shown to promote tissue sparing, reduce cystic cavitation, enhance CNS axon regeneration, remyelinate axons, and enhance endogenous SC myelination resulting in sensorimotor recovery.\textsuperscript{134-138} The growth-promoting properties of SCs are also being exploited in combinatorial therapies. For example, neuroprotectant D15A (a modified human NT3 that can activate both TrkB and TrkC receptors) has been combined with phosphodiesterase-4 inhibitor, rolipram, and SCs to enhance axonal sparing and growth of serotonergic fibers into and beyond the SC graft.\textsuperscript{139} SCs have also been combined with NSC,\textsuperscript{140} OEC,\textsuperscript{74} and BM-MSC\textsuperscript{141} transplants to enhance cell survival and promote additional remyelination.

In humans, The Miami Project to Cure Paralysis conducted a phase I, open-label study (N = 8; NCT02354625) of autologous SC transplants in individuals with chronic AIS grade A-C C5-T12 injuries. The study completed in August 2019 with results pending. The same group conducted an open-label, nonrandomized, noncontrolled, dose-escalation phase I study (N = 6) of autologous SCs transplanted into the lesion epicenter for subacute-intermediate AIS grade A thoracic injuries. SCs were harvested from the sural nerve within 5 to 30 days of injury, expanded in vitro, and transplanted within 4 to 7 weeks of injury. After 1 year, there were no medical, surgical, or neurological complications to indicate that the treatment was unsafe.\textsuperscript{50}

3.6 | Mesenchymal stem cell

MSCs are multipotent, self-renewing connective tissue progenitor cells found throughout the body, particularly in the perivascular region. They have the capacity to regenerate muscles (myocytes), cartilage (chondrocytes), bone (osteoblasts), and fat (adipocytes).\textsuperscript{142,143} They also have favored properties for conducting a clinical trial. Multipotent MSCs expand rapidly,\textsuperscript{144} remain viable after −80°C or liquid nitrogen cryostorage,\textsuperscript{145} demonstrate minimal immunoreactivity after allogenic transplant,\textsuperscript{146} and can be harvested from accessible tissue such as fat, bone marrow, and skeletal muscle.\textsuperscript{147} This has encouraged their translation in multiple fields such as sepsis,\textsuperscript{148} multiple sclerosis,\textsuperscript{149} and arthritis.\textsuperscript{150} In SCI, MSCs have been shown to promote angiogenesis and significantly enhance tissue sparing through neurotrophic signaling and immunomodulation.\textsuperscript{8,56,151,152} There is also evidence that MSCs transplanted directly into the spinal cord can modulate activation of macrophages and promote tissue sparing.\textsuperscript{153,154} However, MSC transplants have shown considerable variability with some studies showing positive effects whereas other studies have shown no benefit (Table 1).

Multiple adipocyte-derived MSC clinical trials are ongoing to assess safety, dosing, and efficacy. The Mayo Clinic is conducting a phase I study (N = 10; clinicaltrials.gov identifier NCT03308565) of $1 \times 10^8$ autologous, adipose-derived MSCs delivered intrathecally into patients with American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade A/B/C injuries from 2 weeks to 1 year prior to transplant. The study will be completed by 2023.

Bone marrow-derived MSCs are also being studied. A phase II/III trial (N = 32; NCT01676441) conducted by Pharmicell Co is assessing $1.6 \times 10^7$ intraparenchymal and $3.2 \times 10^7$ intrathecal autologous bone marrow-derived MSCs in chronic cervical AIS grade B patients with 12 month follow-up of ASIA motor scores, MR Diffusion Tensor Imaging, and electrophysiological parameters. The study is expected to conclude in 2020.

The umbilical cord is an alternate source of MSCs (UC-MSCs). UC-MSCs can be isolated from cord tissue, cord blood, or Wharton’s jelly, a gelatinous substance within the umbilical cord that insulates the blood vessels. Umbilical cord tissue is readily accessible and

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{A simplified schematic representation of a proposed endogenous neural stem cell (NSC) lineage. Within the central nervous system, the proposed lineage suggests two types of NSCs are present. Primitive NSCs (pNSCs) are a population of rare, leukemia inhibitory factor (LIF) responsive cells that give rise to more abundant definitive NSCs (dNSCs). dNSCs are responsive to EGF and FGF2 (EFH). NSC progeny (progenitor cells) give rise to neurons, astrocytes, and oligodendrocytes upon differentiation. This pathway is exploited for ESC- and iPSC-based generation of NSCs, neurons and glia. Direct reprogramming allows somatic cells to enter the NSC or later stage without passing through the pluripotent state.}
\end{figure}
frequently discarded, and MSCs from the umbilical cord are less prone to rejection, as evidenced by a lower risk of developing graft vs host disease.\textsuperscript{155} Compared with adult sources, the number of MSCs obtained from cord blood or placental tissues is small, although they can be readily expanded and tissue can be frozen and used later for isolation.\textsuperscript{156} MSCs derived from the umbilical cord have also been shown to have immunomodulatory properties.\textsuperscript{157} Several recently registered phase I/II trials (NCT03505034; NCT02481440; NCT03521323) are recruiting to assess allogeneic UC-derived MSCs for subacute and chronic SCI. A phase I/II open-label study (N = 14; NCT02981576) in Jordan directly compared adverse effects and AIS improvement with intrathecal adipose- vs bone marrow-derived MSCs in AIS A/B/C patients 2 or more weeks postinjury. The study completed in January 2019 with results pending.

3.7 | Endogenous stem cell therapies

An alternative approach to promote neural repair is to harness the potential of resident stem cells, such as NSCs within the injured CNS.\textsuperscript{158,159} This approach circumvents immunorejection, cell delivery challenges and logistical hurdles such as good manufacturing practice (GMP) scale-up, cell storage, and transport. Within the spinal cord, it has been demonstrated that NSCs respond to injury by proliferating\textsuperscript{160} and migrating to the lesion, although the effect is likely insufficient to generate recovery.\textsuperscript{29,159} Recently, small molecules, such as the FDA-approved drugs cyclosporin A and Metformin, have been found to increase the size of the endogenous pNSC and dNSC pool to augment this intrinsic injury response.\textsuperscript{161,162} Cyclosporin A is an immunosuppressive medication that has been shown to enhance survival of NSCs and promote recovery within the brain.\textsuperscript{161,162} Activation of NSCs with cyclosporin A has also been observed in the spinal cord and ongoing investigations aim to elucidate its effect following SCI.\textsuperscript{161,162} Metformin, a drug commonly used to treat type II diabetes, has also been shown to activate endogenous NSCs and direct their differentiation toward neurons and oligodendrocytes.\textsuperscript{110,159} Although molecular mechanisms underlying these effects have not been elucidated, metformin administration has been shown to improve functional recovery after insult to the brain.\textsuperscript{110,159} Studies of metformin in SCI animal models are ongoing. Additional targets being explored to enhance the endogenous NSC response are the C-Kit and ErbB2 signaling pathways.\textsuperscript{163}

4 | ENHANCING CELL TRANSPLANTATION THERAPIES

Transplanted cell survival has historically been low in animal models of SCI.\textsuperscript{164} This is typically overcome by delivering excess numbers of cells to compensate for losses; however, this approach introduces variability into the therapy, contributes cytotoxic by-products of cell death to the microenvironment, and becomes infeasible when large numbers of surviving cells are required. Ongoing work seeks to enhance cell survival, migration, and axonal outgrowth by overcoming key barriers in the SCI microenvironment.

4.1 | Growth factors

To support graft survival, growth factors (eg, PDGF, EGF, and IGF-1), neurotrophins (eg, BDNF, NT3, NGF), and anti-inflammatory agents (eg, minocycline) have all been successfully delivered via intrathecal injections and pumps.\textsuperscript{65,164-166} Unique biomaterials have also been engineered to gradually deliver key factors to support grafts.\textsuperscript{167} Growth factors and treatments such as ferritin are also associated with enhanced endogenous OPC proliferation and oligodendrogenesis. However, pumps are prone to failure, require refilling and explant procedures, and expose growth factors to mammalian body temperatures for prolonged periods. As a result, alternate approaches continue to be investigated such as the codelivery of cells with biomaterials capable of slowly releasing growth factors directly into the environment. This unique strategy is discussed further in the Biomaterials section below. Another approach is the in vitro genetic modification of cells or the in vivo transfection of endogenous cells to secrete the necessary factors. For example, MSCs have been successfully engineered to express bFGF,\textsuperscript{168} HGF,\textsuperscript{169} NT3,\textsuperscript{170} BDNF,\textsuperscript{171} and GDNF\textsuperscript{172} in vivo for various applications. SCs have also been transduced to overexpress BDNF and NT3 simultaneously.\textsuperscript{173} Similarly, safe and highly efficient methods of engineering human iPSCs, ESCs, and NSCs are currently being developed.

4.2 | Rehabilitation

An often overlooked method of promoting endogenous trophic factor release and long-term cell survival noninvasively is rehabilitation. Physical rehabilitation, with or without electroceutical augmentation, is an integral component of the care plan for individuals with SCI; however, it is underrepresented in preclinical trials. Whether the rehabilitation entails forced treadmill training, free swimming, or task-specific tests such as forelimb reaching, the functional benefits can be significant.\textsuperscript{174} In addition to enhancing cardiorespiratory and musculoskeletal function, treadmill locomotor training has been found to enhance transplanted NSC survival by more than fivefold through increased IGF-1 signaling.\textsuperscript{175} This finding underscores the value of multimodality, interdisciplinary care in SCI.

4.3 | Biomaterials

Biomaterials can enhance cell-based approaches for SCI in several ways. Scaffolds derived from either natural or synthetic polymers have been implanted within the lesion cavity to bridge the gap to serve as a substrate for axonal growth and cell migration.\textsuperscript{176-180} InVivo Therapeutics’ Neuro-Spinal Scaffold is a porous bioresorbable polymer scaffold shown to promote appositional healing, white matter sparing, and normalization of intraparenchymal tissue pressure in preclinical models of SCI.\textsuperscript{181} A
Scaffolds can also provide a physical substrate for seeded cells and provide directional guidance for axons. Moreover, biomaterials can also be used as vehicles to deliver cells and release growth factors to aid in graft cell survival, integration, and differentiation. Injectable in situ polymerizing hydrogels can deliver cells and factors directly into a lesion site with less invasive surgical interventions. For example, a polymer blend of hyaluronan/methylcellulose (HAMC) is injectable, in situ gelling, biodegradable, and noncytotoxic. QL6 is an exciting SCI and, when codelivered with growth factors, have been shown to promote the survival of transplanted stem cells after graft cell survival, integration, and differentiation of human iPSC-derived OPCs. QL6 injected with NSCs improved graft survival, reduced glial scarring and inflammation, and improved forelimb function in cervical models of SCI.

**4.4 | Galvanotaxis**

Electrical fields (EFs) are a physical environmental cue present within living tissue. During development, multipotent cells rely on these fields for appropriate migration and differentiation. If the fields are disrupted, severe defects can result. EFs have also been shown to guide cells in adults after injury. Therapeutic galvanotaxis (the directed migration of cells in an electric field) exploits the electrosensitivity of cells to promote migration using externally applied EFs. This has been shown to be feasible with SCs, NSCs, and many other cell types. Both endogenous and transplanted NSCs, but not their differentiated progeny, have been shown to migrate with transcranial direct current electrical stimulation; however, directed migration will require further optimization to establish the ideal current, voltage, phase, lead placement, and timing of EF application.

**4.5 | Disrupting the glial scar**

The glial/CSPG scar is well established in chronic injury and limits axon regeneration through the lesional/perilesional region (Figure 1C). A meta-analysis of NSC treatments found motor function recovered to a greater extent with cell delivery in the acute phase (SMD = 1.80; 95% CI: 1.36-2.24) or subacute phase (SMD = 1.38; 95% CI: 1.08-1.67) than in the chronic phase (SMD = 1.04; 95% CI: 0.47-1.60; P = .03) of injury highlighting the difficulty in regenerating the chronically injured spinal cord.

As a result, numerous labs have focused on methods to disrupt the glial/CSPG scar during or prior to cell transplant. Chondroitinase ABC (ChABC) is a bacterial enzyme which rapidly degrades the long glycosaminoglycan (GAG) side chains of CSPGs. Another exciting approach is to inhibit the association of the protein tyrosine phosphatase σ receptor with its CSPG ligand. An example is Intracellular Sigma Peptide (ISP) which is administered subcutaneously after injury, crosses the BSCB, and results in significant axonal regrowth within the injured cord. ISP has also been shown to indirectly immunomodulate when combined with leukocyte antigen-related receptor blockade.

**5 | TRANSLATING STEM CELL THERAPIES**

**5.1 | Graft survival**

A major challenge in translating cell therapies to clinic is assessing and optimizing graft survival. Culture and storage conditions, characterization pipelines, and transplant conditions can be significantly different in the laboratory than in clinical trial or routine use. Furthermore, commonly employed graft assessment techniques such as immunohistochemistry and bioluminescent tagging are typically not possible in humans. Strategies discussed previously such as increased trophic support, timed rehabilitation, and codelivering biomaterials may prove to be important adjuvants in advancing cell therapy for humans. These are in early deployment such as the Neuro-Spinal Scaffold (NCT02138110) by InVivo Therapeutics Inc or the phase I/II study of MSCs and NSCs using the NeuroRegen scaffold (NCT02688049). Assessing grafted cells in vivo may also become viable as novel MRI-based cell trackers are developed.

**5.2 | Immunorejection**

Another important translational hurdle is understanding and overcoming potential immunorejection within the CNS. The extent and temporality of cell graft rejection within the human CNS is currently unknown. Additionally, the cell source (eg, autologous, allogenic, genetically modified, etc) may significantly affect downstream graft survival in humans. Enhancing endogenous cell proliferation is one strategy to avoid immunorejection; however, endogenous cell pools may still be limited and...
optimal methods to drive their differentiation and migration have not yet been established.\textsuperscript{217} Recently, genetic techniques which modify major histocompatibility complexes and CD47 have been shown to generate immune-evasive iPSC lines.\textsuperscript{218} This may become an important strategy in the future to protect grafts from immune cells.

5.3 | GMP-grade scale-up

Effective translation of cell therapies into clinical trial and beyond requires careful planning of GMP facilities and scale-up strategies. Many challenges of GMP-grade production are not typically encountered in a research setting and are associated with significant financial costs. For example, all manual handling must be highly reproducible between facilities and occur in stringent GMP-grade clean rooms. Standard operating procedures must be established and compliance must be traceable throughout the production chain.\textsuperscript{212} Cultures are typically free of animal products (eg, proteins, feeder cells, etc.), unless more suitable options are not available, and all reagents require qualification as meeting the standards for GMP-grade culture.\textsuperscript{212} Common viral transduction and nonviral transfection (eg, electroporation, lipofection) techniques require additional steps to validate that risks inherent to viral particles or foreign DNA have been mitigated. Furthermore, master and working cell banks must be established with extensive testing for bacteria, viruses, fungi, mycoplasma, and endotoxins at each step of preparation. It is also important to note that during this translational process, the research cell line with which preclinical efficacy was validated, may not be the same as the final clinical cell line for trial which may necessitate additional efficacy testing in animal models.\textsuperscript{219}

The importance of cell line and subline testing is apparent when addressing the potential for tumor formation as graft-derived tumors can occur in rigorously tested and banked lines due to the multiple potential etiologies of tumorigenicity.\textsuperscript{220,221} As a living therapy, even small variations in transport, subculture, or transplant technique at individual centers hold the potential to alter the phenotype of the graft. Furthermore, lines are typically characterized by sampling a portion of the larger population; however, tumor formation can occur due to a single aberrant cell. Advanced technologies, such as environment-controlled cell culture robots and high-throughput total population screening techniques, seek to address these challenges.\textsuperscript{222,223}

Fortunately, the US FDA and European Medicines Agency have provided regulatory frameworks to begin approaching the complexities of GMP cell manufacturing.\textsuperscript{224,225} Additionally, networks of GMP-grade facilities, such as the CellCAN Regenerative Medicine and Cell Therapy Network in Canada, have been established to aid in navigating these challenges.\textsuperscript{226}

5.4 | Storage and transport

Conducting clinical trials or treatments across multiple sites requires a coordinated storage and transportation approach capable of accommodating international shipping delays and unexpected package handling conditions. For example, a study of human MSCs found that cells stored at 2°C to 8°C were sensitive to 25 Hz vibrations,\textsuperscript{227} leading to cell death and increases in MSC marker expression such as CD29 and CD44.\textsuperscript{228} Similarly, temperature and repeated freeze-thaw cycles have a significant effect on cell viability. Cryoprotectant toxicity, rapid osmotic shifts, ice crystal formation, and activation of apoptosis are key mechanisms underlying cell death during the process.\textsuperscript{229} Early studies achieved human cryopreserved pluripotent cell survival rates of only 30% or less.\textsuperscript{230} As a result, other cold storage techniques have been developed such as vitrification, the rapid cooling of cells in high concentrations of cryoprotectants to inhibit ice formation. These were found to provide >75% survival but add technical complexity and may be limiting in the production of large-scale banks.\textsuperscript{229} Furthermore, the storage solution (eg, DMSO, polyethylene glycol, etc.) and additives (eg, ROCK-inhibitor, trehalose, poly-L-lysine, etc.) exert their own effects on the survival and differentiation of stored cells.\textsuperscript{229} Therefore, each cell type and cell line requires optimization to establish ideal conditions for a functional and reliable supply chain.

5.5 | Patient selection

Establishing the ideal patient population for cell transplant in SCI is challenging. Given the currently high cost and limited availability of GMP-grade cell therapies, one strategy is to focus on populations with the greatest potential gains. Cervical cord injuries are the most common and can result in devastating impairments in activities of daily living (eg, feeding, grooming, transferring) and are often associated with respiratory and autonomic complications.\textsuperscript{47} Even modest improvements in key muscle groups such as grip and elbow flexion can have profound benefits for quality of life making this an important population for inclusion in cell-based studies. It is, however, important to balance these inclusion benefits with potential risks. The cervical SCI population can be more expensive to study in trial as hospital stay, treatment, and rehabilitation costs are higher.\textsuperscript{2} Additionally, limiting studies to highly specific study regions can make recruitment more challenging.

Another key consideration is transplant timing. Due to differences in physiology, injury etiology, cord architecture, patient comorbidities, and a host of microenvironmental cell signals, the optimal timing for transplant in animal models likely differs from humans.\textsuperscript{15} Furthermore, even with established infrastructure, there is often a lead time associated with delivering banked cells (eg, allogeneic therapy) or generating a cell line (eg, autologous therapy).\textsuperscript{231} Therefore, many trials are now conducted in the intermediate to chronic phases of injury where the patients’ condition and neurologic status are better established and study recruitment is less complex. However, overcoming regenerative barriers in chronic SCI such as the glial scar and cystic cavitation may require some of the innovative strategies discussed previously.
Adapting delivery techniques is a key facet of translating cell therapies. Systemic or intrathecal treatments avoid many challenges by using existing, well-established medical techniques; however, the distribution of cells is poorly controlled. For intraparenchymal treatments (Figure 3), trials are increasingly utilizing standardized, tightly controlled delivery systems which must be scaled for human doses, provide high reliability, allow sterilization, and have undergone regulatory approval as a medical device.232

The two main classes of injectors currently in use are table-mounted and spine-mounted systems. Table-mounted injectors233,234 provide a high degree of injection cannula stability along all three axes but do not account for cord movement due to ventilation, cardiovascular pulsations, or other patient movement. Spine-mounted devices are typically immobilized on pedicle screws or by clamping the posterior vertebral arch to account for respiration but may not account for all cord pulsations. Recently, a floating cannula system has also been developed which compensates for these natural pulsations to further improve targeting.235 A third class of devices is also under development which utilizes tools mounted on surgical robots, such as the da Vinci Surgical System (Intuitive Surgical Inc), for highly precise localization.

FIGURE 3 Potential considerations during intraparenchymal transplant of stem cells into the spinal cord. These considerations apply to perilesional parenchymal transplants; however, other considerations apply when transplanting directly into lesion or cavity sites where parenchymal volume and cord architecture are already lost. A, Stem cell grafts can be delivered by fine needles or catheters to the gray matter (ventral horn, dorsal horn, etc.) or white matter (dorsal tracts, lateral tracts, ventral tracts, etc.). The spinal cord is most commonly approached dorsally; however, dorsolateral and ventral techniques are also possible depending on the surgical approach. B, Multiple factors affect graft delivery. Higher syringe injection speeds lead to compressive forces on the graft, however, lower speeds increase operative time and allow cell-cell adhesion to occur which can clog the needle or cause membrane disruption. Thin needles can cause greater shearing forces on cells as they exit the tip, whereas thick needles cause greater parenchymal damage and potentially allow a wider needle tract for graft efflux. Larger transplant volumes allow larger doses of cells; however, volumes are limited by surrounding tissue. Respiratory and cardiac cycles typically continue during grafting, which can potentially cause microtrauma and cell efflux around the transplant needle.

5.6 Delivery techniques

6 OUTLOOK

The multifaceted pathophysiology of SCI and the complexities of neural repair and regeneration necessitate novel approaches to treatment. Cell-based therapies continue to be very attractive and hopeful strategies for repair of SCI and the rapid pace of innovation continues to increase as our understanding of fundamental cell biology deepens. We predict that as the timing, dose, and delivery of adult- and pluripotent stem cell-derived treatments are optimized, increasing numbers of cell-based therapies will be translated to humans. It is highly likely that successful approaches will integrate strategies to enhance and support cells, such as genetic engineering, biomaterials, galvanotaxis, and scar degradation to maximize clinical outcomes. Ongoing preclinical and clinical trials highlight the excitement and tremendous progress that has been made in the field and underscore the importance of the collaborative work being conducted by researchers, clinicians, stakeholders, and funding agencies worldwide.

ACKNOWLEDGMENTS

The authors thank Dr. Wolfram Tetzlaff from the University of British Columbia, Canada for insightful discussions and providing critical feedback on this article. Michael G. Fehlings would like to acknowledge support from the Gerry and Tootsie Halbert Chair in Neural
CONFLICT OF INTEREST
Michael G. Fehlings declared advisory role with Fortuna Fix. The other authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS
C.S.A., A.M.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; M.K., J.H.B., E.A.G., D.V.D.K., C.M.M., C.T.: manuscript writing, final approval of manuscript; M.G.F.: conception and design, financial support, manuscript writing, final approval of manuscript.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID
Michael G. Fehlings https://orcid.org/0000-0002-5722-6364

REFERENCES
1. Christopher & Dana Reeve Foundation. 2010. One degree of separation: paralysis and spinal cord injury in the United States.
2. National Spinal Cord Injury Statistical Center. Facts and Figures at a Glance. Birmingham, AL: University of Alabama at Birmingham; 2018.
3. Ahuja CS, Martin AR, Fehlings M. Recent advances in managing a spinal cord injury secondary to trauma. F1000Res. 2016;5:1–12.
4. Ahuja CS, Nori S, Tetreault L, et al. Traumatic spinal cord injury-repair and regeneration. Neurosurgery. 2017;80:59–522.
5. Bachem LD, Ahuja CS, Fehlings MG. Assessment and management of acute spinal cord injury: from point of injury to rehabilitation. J Spinal Cord Med. 2017;40:665–675.
6. Ahuja CS, Schroeder GD, Vaccaro AR, Fehlings MG. Spinal cord injury-what are the controversies? J Orthop Trauma. 2017;31(Suppl 4):S7–S13.
7. Khazaai M, Ahuja CS, Fehlings MG. Induced pluripotent stem cells for traumatic spinal cord injury. Front Cell Dev Biol. 2017;5:1–9.
8. Undreaj A, Chio JC, Ahuja CS, Fehlings MG. Modulating the immune response in spinal cord injury. Expert Rev Neurother. 2016;16:1127–1129.
9. Chen Y, He Y, DeVivo MJ. Changing demographics and injury profile of new traumatic spinal cord injuries in the United States, 1972-2014. Arch Phys Med Rehabil. 2016;97:1610–1619.
10. van den Berg ME, Castellote JM, Mahillo-Fernandez I, de Pedro-Cuesta J. Incidence of spinal cord injury worldwide: a systematic review. Neuroepidemiology. 2010;34:184–192. discussion 192.
11. Lenahan B, Street J, Kwon BK, et al. The epidemiology of traumatic spinal cord injury in British Columbia, Canada. Spine (Phila Pa 1976). 2012;37:321–329.
12. DeVivo MJ, Chen Y. Trends in new injuries, prevalent cases, and aging with spinal cord injury. Arch Phys Med Rehabil. 2011;92:332–338.
13. LaPlaca MC, Simon CM, Prado GR, Cullen DK. CNS injury biomechanics and experimental models. Prog Brain Res. 2007;161:13–26.
14. Choo AM, Liu J, Lam CK, Dvorak M, Tetzlaff W, Oxland TR. Contusion, dislocation, and distraction: primary hemorrhage and membrane permeability in distinct mechanisms of spinal cord injury. J Neurosurg Spine. 2007;6:255–266.
15. Ahuja C, Wilson JR, Nori S, et al. Traumatic spinal cord injury. Nat Rev Dis Primers. 2017;3:1–21.
16. Pineau I, Lacroix S. Proinflammatory cytokine synthesis in the injured mouse spinal cord: multiphasic expression pattern and identification of the cell types involved. J Comp Neurol. 2007;500:267–285.
17. Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H. Free radical-induced damage to DNA: mechanisms and measurement. This article is part of a series of reviews on “Oxidative DNA Damage and Repair.” The full list of papers may be found on the homepage of the journal. Guest editor: Mirla Dizdaroglu. Free Radic Biol Med. 2002;32:1102–1115.
18. Hausmann ON. Post-traumatic inflammation following spinal cord injury. Spinal Cord. 2003;41:369–378.
19. Liu M, Wu W, Li H, et al. Necroptosis, a novel type of programmed cell death, contributes to early neural cells damage after spinal cord injury in adult mice. J Spinal Cord Med. 2015;38:745–753.
20. Wang Y, Wang H, Tao Y, Zhang S, Wang J, Feng X. Necroptosis inhibitor necrostatin-1 promotes cell protection and physiological function in traumatic spinal cord injury. Neuroscience. 2014;266:91–101.
21. Li S, Mealing GA, Morley P, Stys PK. Novel injury mechanism in anoxia and trauma of spinal cord white matter: glutamate release via reverse Na+-dependent glutamate transport. J Neurosci. 1999;19:RC16.
22. Li S, Stys PK. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter. J Neurosci. 2000;20:1190–1198.
23. Ahuja CS, Wilson JR, Nori S, et al. Traumatic spinal cord injury. Rev Dis Primers. 2017;3:17018.
24. Kwon B. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J. 2004;4:451–464.
25. Pathania S, Bagler G, Ahuja PS. Differential network analysis reveals evolutionary complexity in secondary metabolism of Rauvolfia serpentina over Catharanthus roseus. Front Plant Sci. 2016;7:1229.
26. Tator CH. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol. 1995;5:407–413.
27. Milhorat TH, Capocelli AL, Anzil AP, Kotzen RM, Milhorat RH. Pathological basis of spinal cord cavitation in syringomyelia: analysis of 105 autopsy cases. J Neurol. 1995;82:802–812.
28. Jeffery ND, Blakemore WF. Locomotor deficits induced by experimental spinal cord demyelination are abolished by spontaneous remyelination. Brain. 1997;120(Pt 1):27–37.
29. Barnabe-Heider F, Goritz C, Sabelstrom H, et al. Origin of new glial cells in intact and injured adult spinal cord. Cell Stem Cell. 2010;7:470–482.
30. Goritz C, Dias DO, Tomilin N, Barbadic M, Shupliakov Q, Frisen J. A pericyte origin of spinal cord scar tissue. Science. 2011;333:238–242.
31. Meletis K, Barnabe-Heider F, Carlen M, et al. Spinal cord injury reveals multilineage differentiation of ependymal cells. PLoS Biol. 2008;6:e182.
32. Soderblom C, Luo X, Blumenthal E, et al. Perivascular fibroblasts form the fibrotic scar after contusive spinal cord injury. J Neurosci. 2013;33:13882–13887.
33. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci. 2004;5:146–156.
34. Lang BT, Cregg JM, DePaul MA, et al. Modulation of the proteoglycan receptor PTigin promotes recovery after spinal cord injury. Nature. 2015;518:404–408.
35. McKeon RJ, Schreiber RC, Rudge JS, Silver J. Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J Neurosci. 1991;11:3398–3411.
36. Forgione N, Fehlings MG. Rho-ROCK inhibition in the treatment of spinal cord injury. *World Neurosurg*. 2014;82:e535-e539.

37. Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. *Nature*. 2000;403:434-439.

38. Moreau-Fauvarque C, Kumanogoh A, Camand E, et al. The transmembrane semaphorin Sema4D/CD1100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. *J Neurosci*. 2003;23:9229-9239.

39. Cizkova D, Rosocha J, Vanicky I, Jergova S, Cizek M. Transplants of bone marrow stromal cells enhance differentiation of cocultured neurosphere cells and promote regeneration of injured spinal cord. *J Neurosci Res*. 2003;72:343-351.

40. Wu S, Suzuki Y, Ejiri Y, et al. Bone marrow stromal cells enhance differentiation of cocultured neurosphere cells and promote regeneration of injured spinal cord. *J Neurosci Res*. 2003;72:343-351.

41. Ohta M, Suzuki Y, Noda T, et al. Bone marrow stromal cells infused into the cerebrospinal fluid promote functional recovery of the injured rat spinal cord with reduced cavity formation. *Exp Neurol*. 2004;187:266-278.

42. Ankeny DP, McTigue DM, Jakeman LB. Bone marrow transplants provide tissue protection and directional guidance for axons after contusive spinal cord injury in rats. *Exp Neurol*. 2004;190:17-31.

43. Urdzikova L, Jendelova P, Glogarova K, Burian M, Hajek M, Sykova E. Transplantation of bone marrow stem cells as well as mobilization by granulocyte-colony stimulating factor promotes recovery after spinal cord injury in rats. *J Neurotrauma*. 2006;23:1379-1391.

44. Park SI, Lim JY, Jeong CH, et al. Human umbilical cord blood-derived mesenchymal stem cell therapy promotes functional recovery of contused rat spinal cord through enhancement of endogenous cell proliferation and oligogenesis. *J Biomed Biotechnol*. 2012:2012;362473.

45. Menezes K, Nascimento MA, Goncalves JP, et al. Human mesenchymal cells from adipose tissue deposit laminin and promote regeneration of injured spinal cord in rats. *PLoS One*. 2014;9:e96020.

46. Parr AM, Kulbatski I, Zahir T, et al. Transplanted adult spinal cord-derived neural stem/progenitor cells promote early functional recovery after rat spinal cord injury. *Neuroscience*. 2008;155:760-770.

47. Parr AM, Kulbatski I, Tator CH. Transplantation of adult rat spinal cord stem/progenitor cells for spinal cord injury. *J Neurotrauma*. 2007;24:835-845.

48. Karimi-Abdolrezaee S, Eftekharpour E, Wang J, Morshed CM, Fehlings MG. Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury. *J Neurosci*. 2006;26:3377-3389.

49. Karimi-Abdolrezaee S, Eftekharpour E, Wang J, Schut D, Fehlings MG. Synergistic effects of transplanted adult neural stem/progenitor cells, chondroitinase, and growth factors promote functional repair and plasticity of the chronically injured spinal cord. *J Neurosci*. 2010;30:1657-1676.

50. Cummings BJ, Uchida N, Tamaki SJ, et al. Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. *Proc Natl Acad Sci USA*. 2005;102:14069-14074.

51. Iwanami A, Kaneko S, Nakamura M, et al. Transplantation of human neural stem cells for spinal cord injury in primates. *J Neurosci Res*. 2005;80:182-190.

52. Nori S, Okada Y, Yasuda A, et al. Grafted human-induced pluripotent stem-cell-derived neurons promote motor functional recovery after spinal cord injury in mice. *Proc Natl Acad Sci USA*. 2011;108:16825-16830.

53. Fujimoto Y, Abehara M, Falck A, et al. Treatment of a mouse model of spinal cord injury by transplantation of human induced pluripotent stem cell-derived long-term self-renewing neuroepithelial-like stem cells. *STEM CELLS*. 2012;30:1163-1173.

54. McDonald JW. Repairing the damaged spinal cord. *Sci Am*. 1999;281:64-73.

55. Keirstead HS, Nistor G, Bernal G, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. *J Neurosci*. 2005;25:4694-4705.

56. Sharp J, Frame J, Siegenthaler M, Nistor G, Keirstead HS. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord injury. *STEM CELLS*. 2010;28:152-163.

57. Guest JD, Rao A, Olson L, Bunge MB, Bunge RP. The ability of human Schwann cell grafts to promote regeneration in the transplanted nude rat spinal cord. *Exp Neurol*. 1997;148:502-522.

58. Takami T, Oudega M, Bates ML, Wood PM, Kleitman N, Bunge MB. Schwann cell but not olfactory ensheathing glia transplants improve hindlimb locomotor performance in the moderately contused adult rat thoracic spinal cord. *J Neurosci*. 2002;22:6670-6681.
73. Barakat DJ, Gagliani SM, Neravettia SR, et al. Survival, integration, and axon growth support of glia transplanted into the chronically contused spinal cord. **Cell Transplant.** 2005;14:225-240.

74. Pearse DD, Sanchez AR, Pereira FC, et al. Transplantation of Schwann cells and/or olfactory ensheathing glia into the contused spinal cord: survival, migration, axon association, and functional recovery. **Glia.** 2007;55:976-1000.

75. Li Y, Field PM, Raisman G. Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells. **Science.** 1997;277:2000-2002.

76. Ramon-Cueto A, Cordero MI, Santos-Benito FF, Avila J. Functional recovery of paraplegic rats and motor axon regeneration in their spinal cords by olfactory ensheathing glia. **Neuron.** 2000;25:425-435.

77. Chhabra HS, Sarda K, Arora M, et al. Autologous bone marrow cell transplantation in acute spinal cord injury—an Indian pilot study. **Spinal Cord.** 2016;54:57-64.

78. Mendonca MV, Larocca TF, de Freitas Souza BS, et al. Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury. **J Cell Sci Res Ther.** 2014;5:126.

79. El-Kheir WA, Gabr H, Awad MR, et al. Autologous bone marrow-derived cell therapy combined with physical therapy induces functional improvement in chronic spinal cord injury patients. **Cell Transplant.** 2014;23:729-745.

80. Hur JW, Cho TH, Park DH, Lee JB, Park JY, Chung YG. Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: a human trial. **J Spinal Cord Med.** 2016;39:655-664.

81. Ra JC, Shin IS, Kim SH, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. **Stem Cells Dev.** 2011;20:1297-1308.

82. Satti HS, Waheed A, Ahmed P, et al. Autologous mesenchymal stromal cell transplantation for spinal cord injury: a phase I pilot study. **Cytotherapy.** 2016;18:518-522.

83. Levi AD, Okonkwo DO, Park P, et al. Emerging safety of intra-medullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury. **Neurosurgery.** 2018;82:562-575.

84. Assinck P, Duncan GJ, Hilton BJ, Plemel JR, Tetzlaff W. Cell transplantation therapy for spinal cord injury. **Nat Neurosci.** 2017;20:637-647.

85. Mothe AJ, Zahir T, Santaguida C, Cook D, Tator CH. Neural stem/progenitor cells from the adult human spinal cord are defined conditions. **Cell Stem Cell.** 2011;9:113-118.

86. Chaddah R, Amtfield M, Runciman S, Clarke L, van der Kooy D. Clonal neural stem cells from human embryonic stem cell colonies. **J Neurosci.** 2012;32:7771-7781.

87. Umbebayashi D, Coles B, van der Kooy D. Enrichment of oligodendrocyte progenitors from differentiated neural precursors by clonal sphere preparations. **Stem Cells Dev.** 2016;25:712-728.

88. Colasante G, Rubio A, Massimino L, Broccoli V. Direct neuronal reprogramming reveals unknown functions for known transcription factors. **Front Neurosci.** 2019;13:283.

89. Ambasudhan R, Talantova M, Coleman R, et al. Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. **Cell Stem Cell.** 2011;9:224-227.

90. Sachewsky N, Morshead CM. Prosurvival factors derived from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor. **J Neurosci.** 1996;16:1091-1100.

91. Ambasudhan R, Talantova M, Coleman R, et al. Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. **Cell Stem Cell.** 2011;10:110-118.

92. Colasante G, Lignani G, Rubio A, et al. Rapid conversion of fibroblasts into functional forebrain GABAergic interneurons by direct genetic reprogramming. **Cell Stem Cell.** 2015;17:719-734.

93. Martens DJ, Seaberg RM, van der Kooy D. In vivo infusions of exogenous growth factors into the fourth ventricle of the adult mouse brain increase the proliferation of neural progenitors around the fourth ventricle and the central canal of the spinal cord. **Eur J Neurosci.** 2002;16:282-293.

94. Wilson L, Maden M. The mechanisms of dorsoventral patterning in the vertebral neural tube. **Dev Biol.** 2005;282:1-13.

95. Kulbatski I, Mothe AJ, Keating A, Akamata Y, Kobayashi E, Tator CH. Oligodendrocytes and radial gla derived from adult rat spinal cord progenitors: morphological and immunocytochemical characterization. **J Histochem Cytochem.** 2007;55:209-222.

96. Martens DJ, Seaberg RM, van der Kooy D. In vivo infusions of exogenous growth factors into the fourth ventricle of the adult mouse brain increase the proliferation of neural progenitors around the fourth ventricle and the central canal of the spinal cord. **Eur J Neurosci.** 2002;16:1045-1057.

97. Mothe AJ, Zahir T, Santaguida C, Cook D, Tator CH. Neural stem/progenitor cells from the adult human spinal cord are multipotent and self-renewing and differentiate after transplantation. **PLoS One.** 2011;6:e20709.

98. Weiss S, Dunne C, Hewson J, et al. Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxial. **J Neurosci.** 1996;16:7599-7609.

99. Hitoshi S, Seaberg RM, Koscik C, et al. Primate neural stem cells from the mammalian epiblast differentiate to definitive neural stem cells under the control of notch signaling. **Genes Dev.** 2004;18:1806-1811.

100. Xu W, Lakshman N, Morshed CM. Building a central nervous system: the neural stem cell lineage revealed. **Neurogenesis (Austin).** 2017;4:e1300037.

101. Sachewsky N, Morshed CM. Prosurvival factors derived from the embryonic brain promote adult neural stem cell survival. **Stem Cells Dev.** 2014;23:2469-2481.

102. Xu W, Lakshman N, Morshed CM. Stem cells in the adult CNS revealed: examining their regulation by myelin basic protein. **Neural Regen Res.** 2016;11:1916-1917.

103. Dadwal P, Mahmud N, Sinai L, et al. Activating endogenous neural precursor cells using metformin leads to neural repair and functional recovery in a model of childhood brain injury. **Stem Cell Rep.** 2015;5:166-173.

104. Yousefifard M, Rahimi-Movaghar V, Nasirinezhad F, et al. Neural stem/progenitor cell transplantation for spinal cord injury treatment: a systematic review and meta-analysis. **Neuroscience.** 2016;322:377-397.
112. Mothe AJ, Tator CH. Review of transplantation of neural stem/progenitor cells for spinal cord injury. *Int J Dev Neurosci*. 2013;31:701-713.

113. Dulin JN, Adler AF, Kumamaru H, et al. Injured adult motor and sensory axons regenerate into appropriate organotypic domains of neural progenitor grafts. *Nat Commun*. 2018;9:84.

114. ClinicalTrials.gov. National Institutes of Health: USA; 2016.

115. All AH, Gharibani P, Gupta S, et al. Early intervention for spinal cord injury with human induced pluripotent stem cells oligodendrocyte progenitors. *PLoS One*. 2015;10:e0116933.

116. Kawabata S, Takano M, Numasawa-Kuroiwa I, et al. Grafted human iPSC cell-derived oligodendrocyte precursor cells contribute to robust Remyelination of demyelinated axons after spinal cord injury. *Stem Cell Rep*. 2016;6:1-8.

117. Zhang YW, Denham J, Thies RS. Oligodendrocyte progenitor cells derived from human embryonic stem cells express neurotrophic factors. *Stem Cells Dev*. 2006;15:943-952.

118. Bergles DE, Roberts JD, Somogyi P, Jahr CE. Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. *Nature*. 2000;405:187-191.

119. Plemel JR, Keough MB, Duncan GJ, et al. Remyelination after spinal cord injury: is it a target for repair? *Prog Neurobiol*. 2014;117:54-72.

120. Myers SA, Bankston AN, Burke DA, Ohri SS, Whitemore SR. Does the preclinical evidence for functional remyelination following myelinating cell engraftment into the injured spinal cord support progression to clinical trials? *Exp Neurol*. 2016;283:560-572.

121. Asterias Biotherapeutics. Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury. Omaha, Nebraska: GlobeNewswire; 2019.

122. Windus LC, Lineburg KE, Scott SE, et al. Lamellipodia mediate the heterogeneity of central olfactory ensheathing cell interactions. *Cell Mol Life Sci*. 2010;67:1735-1750.

123. Silva NA, Cooke MJ, Tam RY, et al. The effects of peptide modified gellan gum and olfactory ensheathing glia cells on neural stem/progenitor cell fate. *Biomaterials*. 2012;33:6345-6354.

124. Zhang J, Chen H, Duan Z, et al. The effects of co-transplantation of olfactory ensheathing cells and Schwann cells on local inflammation environment in the contused spinal cord of rats. *Mol Neurobiol*. 2016;54:943-953.

125. Ekberg JA, St John JA. Olfactory ensheathing cells for spinal cord repair: crucial differences between subpopulations of the glia. *Neural Regen Res*. 2015;10:1395-1396.

126. Roet KC, Verhaagen J. Understanding the neural repair-promoting properties of olfactory ensheathing cells. *Exp Neurol*. 2014;261:594-609.

127. Sasaki M, Lankford KL, Zemedkun M, Kocsis JD. Identified olfactory ensheathing cells transplanted into the transected dorsal funiculus bridge the lesion and form myelin. *J Neurosci*. 2004;24:8485-8493.

128. Watzlawick R, Rind J, Sena ES, et al. Olfactory ensheathing cell transplantation in experimental spinal cord injury: effect size and reporting bias of 62 experimental treatments: a systematic review and meta-analysis. *PLoS Biol*. 2016;14:e1002468.

129. Ramer LM, Au E, Richter MW, Liu J, Tetzlaff W, Roskams AJ. Peripheral olfactory ensheathing cells reduce scar and cavity formation and promote regeneration after spinal cord injury. *J Comp Neurol*. 2004;473:1-15.

130. Mackay-Sim A, Feron F, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial. *Brain*. 2008;131:2376-2386.

131. Dlouhy BJ, Awe O, Rao RC, Kirby PA, Hitchon PW. Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient: case report. *J Neurosurg Spine*. 2014;21:618-622.

132. Chhabra HS, Lima C, Sachdeva S, et al. Autologous olfactory [corrected] mucosal transplant in chronic spinal cord injury: an Indian Pilot Study. *Spinal Cord*. 2009;47:887-895.

133. Li L, Adnan H, Xu B, et al. Effects of transplantation of olfactory ensheathing cells in chronic spinal cord injury: a systematic review and meta-analysis. *Eur Spine J*. 2015;24:919-930.

134. Kanno H, Pearse DD, Ozawa H, Itoi E, Bunge MB. Schwann cell transplantation for spinal cord injury repair; its significant therapeutic potential and prospectus. *Rev Neurosci*. 2015;26:121-128.

135. Williams RR, Bunge MB. Schwann cell transplantation: a repair strategy for spinal cord injury? *Prog Brain Res*. 2012;201:295-312.

136. Honmou O, Felts PA, Waxman SG, Kocsis JD. Restoration of normal conduction properties in demyelinated spinal cord axons in the adult rat by transplantation of exogenous Schwann cells. *J Neurosci*. 1996;16:3199-3208.

137. Sparling JS, Bretzner F, Biemanskie J, et al. Schwann cells generated from neonatal skin-derived precursors or neonatal peripheral nerve improve functional recovery after acute transplantation into the partially injured cervical spinal cord of the rat. *J Neurosci*. 2015;35:6714-6730.

138. Biemanskie J, Sparling JS, Liu J, et al. Skin-derived precursors generate myelinating Schwann cells that promote remyelination and functional recovery after contusion spinal cord injury. *J Neurosci*. 2007;27:9545-9559.

139. Pearse DD, Pereira FC, Marcillo AE, et al. CAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. *Nat Med*. 2004;10:610-616.

140. Niapour A, Karamali F, Nemati S, et al. Cotransplantation of human embryonic stem cell-derived neural progenitors and Schwann cells in a rat spinal cord contusion injury model elicits a distinct neurogenesis and functional recovery. *Cell Transplant*. 2012;21:827-843.

141. Pourheydar B, Joghataei MT, Bakhtiari M, Mehdizadeh M, Yeka Z, Najafzadeh N. Co-transplantation of bone marrow stromal cells with Schwann cells evokes mechanical allodynia in the contusion model of spinal cord injury in rats. *Cell J*. 2012;13:213-222.

142. Fellows CR, Matta C, Zakany R, Khan IM, Mobasheri A. Adipose, bone marrow and synovial joint-derived mesenchymal stem cells for cartilage repair. *Front Genet*. 2016;7:213.

143. Law S, Chaubhuri S. Mesenchymal stem cell and regenerative medicine: regeneration versus immunomodulatory challenges. *Am J Stem Cells*. 2013;2:22-38.

144. Sekiya I, Larson BL, Smith JR, Pochampally R, Cui JG, Prockop DJ. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. *Stem Cells*. 2002;20:530-541.

145. Kotosuki N, Hirose M, Takakura Y, Ogushi H. Cultured autologous human cells for hard tissue regeneration: preparation and characterization of mesenchymal stem cells from bone marrow. *Artif Organs*. 2004;28:33-39.

146. Carrade DD, Affolter VK, Outerbridge CA, et al. Intradermal injection of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions. *Cytotherapy*. 2011;13:1180-1192.

147. Dasari VR, Veeravalli KK, Dinh DH. Mesenchymal stem cells in the treatment of spinal cord injuries: a review. *World J Stem Cells*. 2014;6:120-133.

148. Lalu MM, Sullivan KJ, Mei SH, et al. Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial. *Elife*. 2016;5:e17850.

149. Duleama A. Mesenchymal stem cells in multiple sclerosis - translation to clinical trials. *J Med Life*. 2015;8:24-27.
150. Yan X, Cen Y, Wang Q. Mesenchymal stem cells alleviate experimental rheumatoid arthritis through microRNA-regulated IkappaB expression. *Sci Rep.* 2016;6:28915.

151. Akiyama Y, Radtke C, Kocsis JD. Remyelination of the rat spinal cord by transplantation of identified bone marrow stromal cells. *J Neurosci.* 2002;22:6623-6630.

152. Nakajima H, Uchida K, Guerrero AR, et al. Transplantation of mesenchymal stem cells promotes functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury. *J Neurosci.* 2009;29:14932-14941.

153. Akiyama Y, Radtke C, Kocsis JD. Remyelination of the rat spinal cord by transplantation of mesenchymal stem cells promotes an alternative pathway of macrophage activation and functional recovery after spinal cord injury. *J Neurotrauma.* 2012;29:1614-1625.

154. Boido M, Garbossa D, Fontanella M, Ducati A, Vercelli A. Mesenchymal stem cell transplantation reduces giall cyst and improves functional outcome after spinal cord compression. *World Neurosurg.* 2014;81:183-190.

155. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. *N Engl J Med.* 2001;344:1815-1822.

156. Park DH, Lee JH, Borlongan CV, Sanberg PR, Chung YG, Cho TH. Transplantation of umbilical cord blood stem cells for treating spinal cord injury. *Stem Cell Rev.* 2011;7:181-194.

157. Zhou C, Yang B, Tian Y, et al. Immunomodulatory effect of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on lymphocytes. *Cell Immunol.* 2011;272:33-38.

158. Gregoire CA, Goldenstein BL, Floridilla EM, Barnabe-Heider F, Fernandez KJ. Endogenous neural stem cell responses to stroke and spinal cord injury. *Glia.* 2015;63:1469-1482.

159. Wang J, Gallagher D, DeVito LM, et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. *Cell Stem Cell.* 2012;11:23-35.

160. Namiki J, Tator CH. Cell proliferation and nestin expression in the ependyma of the adult rat spinal cord after injury. *J Neuropathol Exp Neurol.* 1999;58:489-498.

161. Hunt J, Cheng A, Hoyles A, Jervis E, Marshead CM. Cyclosporin A has direct effects on adult neural precursor cells. *J Neurosci.* 2010;30:2888-2896.

162. Sachewsky N, Hunt J, Cooke MJ, et al. Cyclosporin A enhances neural precursor cell survival in mice through a calcineurin-independent pathway. *Di Model Mech.* 2014;7:953-961.

163. Reeve RL, Yaminne SZ, DeVeale B, van der Kooy D. Targeted activation of primitive neural stem cells in the mouse brain. *Eur J Neurosci.* 2016;43:1474-1485.

164. Tetzlaff W, Okon EB, Karimi-Abdolrezaee S, et al. A systematic review of cellular transplantation therapies for spinal cord injury. *J Neurotrauma.* 2011;28:1611-1682.

165. Kojima A, Tator CH. Intrathecal administration of epidermal growth factor and fibroblast growth factor 2 promotes ependymal proliferation and functional recovery after spinal cord injury in adult rats. *J Neurotrauma.* 2002;19:223-238.

166. Kojima A, Tator CH. Epidermal growth factor and fibroblast growth factor 2 cause proliferation of ependymal precursor cells in the adult rat spinal cord in vivo. *J Neuropathol Exp Neurol.* 2000;59:687-697.

167. Kim H, Zahir T, Tator CH, Shoichet MS. Effects of dibutyryl cyclic-AMP on survival and neuronal differentiation of neural stem/progenitor cells transplanted into spinal cord injured rats. *PLoS One.* 2011;6:e21744.

168. Liu WG, Wang ZY, Huang ZS. Bone marrow-derived mesenchymal stem cells expressing the bFGF transgene promote axon regeneration and functional recovery after spinal cord injury in rats. *Neural Res.* 2011;33:686-693.

169. Jung WS, Han SM, Kim SM, et al. Stimulatory effect of HGF-over-expressing adipose tissue-derived mesenchymal stem cells on thymus regeneration in a rat thymus involution model. *Cell Biol Int.* 2014;38:1106-1117.

170. Kim YH, Cho SH, Lee SJ, et al. Growth-inhibitory effect of neurotrophin-3-secreting adipose tissue-derived mesenchymal stem cells on the D283-MED human medulloblastoma cell line. *J Neurooncol.* 2012;106:89-98.

171. Gransee HM, Zhan WZ, Sieck GC, Mantilla CB. Localized delivery of brain-derived neurotrophic factor-expressing mesenchymal stem cells enhances functional recovery following cervical spinal cord injury. *J Neurotrauma.* 2015;32:185-193.

172. Rooney GE, McMahon SS, Ritter T, et al. Neurotrophic factor-expressing mesenchymal stem cells survive transplantation into the contused spinal cord without differentiating into neural cells. *Tissue Eng Part A.* 2009;15:3049-3059.

173. Girard C, Bemelmans AP, Dufour N, et al. Grafs of brain-derived neurotrophic factor and neurotrophin 3-transduced primate Schwann cells lead to functional recovery of the demyelinated mouse spinal cord. *J Neurosci.* 2005;25:7924-7933.

174. Dietz V, Fouad K. Restoration of sensorimotor functions after spinal cord injury. *Brain.* 2014;137:654-667.

175. Hwang DH, Shin HY, Kwon MJ, Choi JY, Ryu BY, Kim BG. Survival of neural stem cell grafts in the lesioned spinal cord is enhanced by a combination of treadmill locomotor training via insulin-like growth factor-1 signaling. *J Neurosci.* 2014;34:12788-12800.

176. Bozkurt G, Mothe AJ, Zahir T, Kim H, Shoichet MS, Tator CH. Chitosan channels containing spinal cord-derived stem/progenitor cells for repair of subacute spinal cord injury in the rat. *Neurosurgery.* 2010;67:1733-1744.

177. Guo X, Zahir T, Mothe A, et al. The effect of growth factors and soluble Nogo-66 receptor protein on transplanted neural stem/progenitor survival and axonal regeneration after complete transaction of rat spinal cord. *Cell Transplant.* 2012;21:1177-1197.

178. Rauch MF, Hynes SR, Bertram J, et al. Engineering angiogenesis following spinal cord injury: a coculture of neural progenitor and endothelial cells in a degradable polymer implant leads to an increase in vessel density and formation of the blood-spinal cord barrier. *Eur J Neurosci.* 2009;29:132-145.

179. Tsai EC, Dalton PD, Shoichet MS, Tator CH. Synthetic hydrogel guidance channels facilitate regeneration of adult rat brainstem motor axons after complete spinal cord transaction. *J Neurotrauma.* 2004;21:789-804.

180. Tsai EC, Dalton PD, Shoichet MS, Tator CH. Matrix inclusion within synthetic hydrogel guidance channels improves specific supraspinal and local axonal regeneration after complete spinal cord transaction. *Biomaterials.* 2006;27:519-533.

181. Layer RT, Ulrich TR, Coric D, et al. New clinical-pathological classification of intraspinal injury following traumatic acute complete thoracic spinal cord injury: postdurotomy/myelotomy observations from the INSPIRE trial. *Neurosurgery.* 2017;64:105-109.

182. Theodore N, Hlbek R, Danielson J, et al. First human implantation of a biosororbable polymer scaffold for acute traumatic spinal cord injury: a clinical pilot study for safety and feasibility. *Neurosurgery.* 2016;79:E305-E312.

183. Gupta D, Tator CH, Shoichet MS. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. *J Biomed Mater Res A.* 2014;106:89-98.

184. Caiacco MJ, Zahir T, Mothe AJ, et al. Characterization of hyaluronan-methylcellulose hydrogels for cell delivery to the injured spinal cord. *J Biomed Mater Res A.* 2013;101:1472-1477.

185. Fisher SA, Tam RY, Shoichet MS. Tissue mimetics: engineered hydrogel matrices provide biomimetic environments for cell growth. *Tissue Eng Part A.* 2014;20:895-898.

186. Mothe AJ, Tam RY, Zahir T, Tator CH, Shoichet MS. Repair of the injured spinal cord by transplantation of neural stem cells in a hyaluronan-based hydrogel. *Biomaterials.* 2013;34:3775-3783.
187. Fuhrmann T, Tam RY, Ballarin B, et al. Injectable hydrogel promotes early survival of induced pluripotent stem cell-derived oligodendrocytes and attenuates longterm teratoma formation in a spinal cord injury model. Biomaterials. 2016;83:23-36.

188. Johnson PJ, Parker SR, Sakiyama-Elbert SE. Fibrin-based tissue engineering scaffolds enhance neural fiber sprouting and delay the accumulation of reactive astrocytes at the lesion in a subacute model of spinal cord injury. J Biomed Mater Res A. 2010;92:152-163.

189. Lu P, Woodruff G, Wang Y, et al. Long-distance axonal growth from human induced pluripotent stem cells after spinal cord injury. Neuron. 2014;83:789-796.

190. Iwasa SN, Babona-Pilipos R, Morshead CM. Environmental factors that influence stem cell migration: an "electric field". J Neuroinflammation. 2012;9:53.

191. Liu Y, Ye H, Satkunendrarajah K, Yao GS, Bayon Y, Fehlings MG. A thermostabilized chABC enhances axonal sprouting and functional recovery after spinal cord injury. Proc Natl Acad Sci USA. 2010;107:3340-3345.

192. Bartus K, James ND, Didangelos A, et al. Large-scale chondroitin sulfate proteoglycan digestion with chondroitinase gene therapy leads to reduced pathology and modulates macrophage phenotype following spinal cord contusion injury. J Neurosci. 2014;34:4822-4836.

193. Nakashima K, Asahara T, Iwatsuki M, Tsuchida T, et al. Cell therapy and tissue engineering scaffolds enhance neural fiber sprouting and delay the accumulation of reactive astrocytes at the lesion in a subacute model of spinal cord injury. J Biomed Mater Res A. 2010;92:152-163.

194. McKeon RJ, Bellamkonda RV. Sustained delivery of thermostabilized chABC enhances axonal sprouting and functional recovery after spinal cord injury. Proc Natl Acad Sci USA. 2010;107:3340-3345.
226. Roy DC, Alarco AM, Isasi R. CellCAN: a unique enabler of regenerative medicine and cell therapy in Canada. Stem Cells Dev. 2014;23 (Suppl 1):24-28.

227. Prażnowski K, Mamala J. Classification of the road surface condition on the basis of vibrations of the sprung mass in a passenger car. Paper presented at: IOP Conference Series: Materials Science and Engineering; 2016:012022.

228. Nikolaev NI, Liu Y, Hussein H, Williams DJ. The sensitivity of human mesenchymal stem cells to vibration and cold storage conditions representative of cold transportation. J R Soc Interface. 2012;9:2503-2515.

229. Hunt CJ. Cryopreservation of human stem cells for clinical application: a review. Transfus Med Hemother. 2011:38:107-123.

230. Heng BC, Kuleshova LL, Bested SM, Liu H, Cao T. The cryopreservation of human embryonic stem cells. Biotechnol Appl Biochem. 2005; 41:97-104.

231. Abraham E, Ahmadian BB, Holderness K, Levinson Y, McAfee E. Platforms for manufacturing allogeneic, autologous and iPSC cell therapy products: an industry perspective. Adv Biochem Eng Biotechnol. 2018;165:323-350.

232. Donnelly EM, Lamanna J, Boulis NM. Stem cell therapy for the spinal cord. Stem Cell Res Ther. 2012;3:24.

233. Mazzini L, Mareschi K, Ferrero I, et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci. 2008;265:78-83.

234. Feron F, Perry C, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain. 2005;128:2951-2960.

235. Raore B, Federici T, Taub J, et al. Cervical multilevel intraspinal stem cell therapy: assessment of surgical risks in Gottingen minipigs. Spine (Phil Pa 1976). 2011;36:E164-E171.

How to cite this article: Ahuja CS, Mothe A, Khazaei M, et al. The leading edge: Emerging neuroprotective and neuroregenerative cell-based therapies for spinal cord injury. STEM CELLS Transl Med. 2020;9:1509–1530. https://doi.org/10.1002/sctm.19-0135